Linzess Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber of Linzess (linaclotide), you may be fielding increasing calls from patients who can't fill their prescription. While Linzess is not listed on the FDA Drug Shortages Database or the ASHP shortage list as of 2026, your patients are experiencing real access barriers driven by cost, insurance requirements, and inconsistent pharmacy stocking. This article gives you a clinical and practical overview of the current situation and how to help your patients navigate it.

Current Linzess Supply Status (2026)

Linzess (linaclotide), manufactured by AbbVie in partnership with Ironwood Pharmaceuticals, is not in shortage. All three dosage strengths—72 mcg, 145 mcg, and 290 mcg capsules—are commercially available. AbbVie reports that approximately 98% of commercial health insurance plans cover Linzess on their formulary.

The patient access barriers are not supply-related—they are driven by:

• High brand-only cost: No generic available until at least 2029; retail price $680–$736/30-day supply
• Insurance prior authorization: Many plans require PA before covering Linzess, with Tier 2–3 placement on most formularies
• Step therapy requirements: Some plans require documented failure of OTC laxatives or other agents before approving Linzess
• Pharmacy stocking gaps: Small or independent pharmacies may not stock Linzess routinely due to its high cost and slower turnover

FDA-Approved Indications Quick Reference

Linzess is a guanylate cyclase-C (GC-C) agonist approved for:

• IBS-C: Adults and pediatric patients 7 years and older (290 mcg once daily for adults; 145 mcg for adults who need lower dose)
• CIC: Adults (145 mcg once daily; 72 mcg if tolerability is a concern)
• Functional Constipation (FC): Pediatric patients 2 years and older (72 mcg once daily for ages 6–17; dosing for ages 2–5 as directed by labeling)

Contraindicated in patients under 2 years of age due to risk of severe diarrhea and fatal dehydration. Also contraindicated in patients with known or suspected mechanical GI obstruction.

Navigating Prior Authorization in 2026

Prior authorization for Linzess is common across commercial, Medicare Part D, and some Medicaid plans. To improve approval rates and speed:

• Document the patient's diagnosis (IBS-C, CIC, or FC) and symptom severity in the clinical record
• Record prior treatment trials and failures (fiber, osmotic laxatives, stimulant laxatives) to satisfy step therapy requirements
• Submit a letter of medical necessity if the plan requires documentation beyond the standard PA form
• Request expedited review when the clinical situation warrants faster processing

AbbVie's Linzess access team can assist with PA support. For HCP resources, visit linzesshcp.com.

Clinical Alternatives When Linzess Is Inaccessible

When patients cannot access Linzess due to cost or coverage barriers, consider these FDA-approved alternatives:

• Plecanatide (Trulance): GC-C agonist; approved for CIC and IBS-C in adults; once daily with or without food; similar efficacy to Linzess per comparative studies; brand-name only
• Lubiprostone (Amitiza): Chloride channel activator; CIC in adults; IBS-C in adult women; generic available at significantly lower cost; main side effect is nausea
• Prucalopride (Motegrity): 5-HT4 agonist; CIC in adults; generic available; monitor for mood changes/suicidality
• Tenapanor (Ibsrela): NHE3 inhibitor; IBS-C in adults only; twice daily; brand-name only; appropriate when GC-C agonist therapy has failed

Savings Resources to Share with Your Patients

Directing patients to the right savings resources can be the difference between adherence and abandonment:

• Linzess Savings Program: Commercially insured patients may pay as little as $30/month (max $2,280/year). Call 1-855-859-5614. Not available for Medicare/Medicaid patients.
• AbbVie Patient Assistance Foundation: For uninsured patients with income-based need—up to 12 months of free medication with reapplication available. Call 1-800-222-6885.
• GoodRx / SingleCare coupons: Reduce cash price from $736 to approximately $252 for 30 capsules at participating pharmacies.

Help Your Patients Find Linzess at a Pharmacy Near Them

When pharmacy stocking is the issue, consider recommending medfinder for providers. medfinder calls pharmacies near your patient to identify which ones have Linzess in stock and can fill the prescription—then texts the patient the results. This removes the burden from both your staff and your patient of calling multiple pharmacies.